Annals of Vascular Diseases
Online ISSN : 1881-6428
Print ISSN : 1881-641X
ISSN-L : 1881-641X
2 巻, 3 号
選択された号の論文の10件中1~10を表示しています
CURRENT TOPICS OF PULMONARY EMBOLISM
ORIGINAL ARTICLE
  • Tsutomu Yamazaki, Masahiko Kurabayashi, the ASTRO-1 Study Group
    2009 年2 巻3 号 p. 148-158
    発行日: 2009/12/31
    公開日: 2010/03/29
    ジャーナル フリー
    Objective: For new evidence of treatment with statins in Japanese hypercholesterolemic patients, we performed an open-label, randomized, parallel-group comparative study to assess the effect of rosuvastatin 2.5 mg and pravastatin 10 mg on plasma lipids.
    Methods: A total of 100 patients in whom the target control levels of LDL-cholesterol (LDL-C) set by the Japan Atherosclerosis Society Guidelines (JASGL2007) had not been achieved were randomly assigned to receive rosuvastatin 2.5 mg / day or pravastatin 10 mg / day for 8 weeks. The primary endpoint was the percent change of LDL-C at week 8.
    Results: LDL-C was lowered by -40.3% (from 160.3 to 95.1 mg / dL) in the rosuvastatin group and -22.9% (from 162.9 to 126.0 mg / dL) in the pravastatin group, at week 8 (P < 0.001 vs. pravastatin). LDL-C / HDL-C ratio was lowered by -41.3% (from 2.85 to 1.69) and -20.6% (from 2.81 to 2.24), respectively (P < 0.001 vs. pravastatin). The rate of achievement of the target LDL-C control level at week 8 was significantly higher in the rosuvastatin group (98.0%) than in the pravastain group (78.7%) (P = 0.003). Both drugs were well tolerated.
    Conclusion: Rosuvastatin 2.5 mg produced significantly greater reduction in LDL-C and beneficial effect on other lipid parameters than pravastatin 10 mg, and its safety profile is similar to pravastatin 10 mg.
  • Tsutomu Yamazaki, Masahiko Kurabayashi, the ASTRO-2 Study Group
    2009 年2 巻3 号 p. 159-173
    発行日: 2009/12/31
    公開日: 2010/03/29
    ジャーナル フリー
    Objective: For new evidence of aggressive lipid lowering treatment with statins in Japanese hypercholesterolemic patients, we performed an open-label, randomized, parallel-group comparative study to assess the effect of rosuvastatin 5 mg and atorvastatin 10 mg on plasma lipids.
    Methods: A total of 900 patients in whom the target control levels of LDL-cholesterol (LDL-C) set by the Japan Atherosclerosis Society Guidelines (JASGL2007) had not been achieved were randomly assigned to receive rosuvastatin 5 mg / day (n = 450) or atorvastatin 10 mg / day (n = 450) for 8 weeks. The primary endpoint was the percent change of LDL-C at week 8.
    Results: LDL-C was lowered by -44.5% (from 170.2 to 93.3 mg / dL) in the rosuvastatin group and -41.6% (from 169.5 to 97.9 mg / dL) in the atorvastatin group, at week 8 (P = 0.002 vs. atorvastatin). LDL-C / HDL-C ratio was lowered by -47.6% (from 3.01 to 1.56) and -43.5 % (from 2.96 to 1.66), respectively, at week 8 (P < 0.001 vs. atorvastatin). The changes in HDL-C, ApoB, ApoA-1, and ApoB / ApoA-1 ratio showed significant improvement in the rosuvastatin group than in the atorvastatin group. Adverse events were observed comparably between the rosuvastatin group (121 events) and the atorvastatin group (104 events). None of these events had adverse clinical consequence. Both drugs were well tolerated.
    Conclusion: Rosuvastatin 5 mg produced significantly greater reduction in LDL-C and beneficial effect on other lipid parameters than atorvastatin 10 mg, and was also well tolerated.
CASE REPORT
feedback
Top